---
title: "Cardiff Oncology To Announce New Data On Onvansertib In Colorectal Cancer Trial Tomorrow"
description: "Cardiff Oncology Inc. (CRDF) will announce new clinical data from its CRDF-004 trial on July 29, 2025. This phase II trial evaluates Onvansertib, a PLK1 inhibitor, in combination with standard treatme"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250443929.md"
published_at: "2025-07-28T14:36:57.000Z"
---

# Cardiff Oncology To Announce New Data On Onvansertib In Colorectal Cancer Trial Tomorrow

> Cardiff Oncology Inc. (CRDF) will announce new clinical data from its CRDF-004 trial on July 29, 2025. This phase II trial evaluates Onvansertib, a PLK1 inhibitor, in combination with standard treatments for RAS-mutated metastatic colorectal cancer. Initial results showed an objective response rate of 64% for the 30mg Onvansertib dose compared to 33% for the control. The drug was well tolerated at both tested doses. Currently, CRDF's stock is at $3.91, down 1.51%.

Cardiff Oncology Inc. (CRDF), a clinical-stage biotechnology company, is expected to share additional clinical data from its ongoing CRDF-004 trial on July 29, 2025.

CRDF-004 is a phase II trial evaluating the company's drug candidate, Onvansertib, a PLK1 inhibitor, in combination with standard of care (SoC) therapeutics as a 1st line treatment of patients with a RAS-mutated metastatic colorectal cancer. In this study, patients are being randomized in a 1:1:1 ratio to either 20mg of Onvansertib plus SoC, 30mg of Onvansertib plus SoC, or SoC alone. The SoC consists of FOLFIRI plus Bevacizumab or FOLFOX plus Bevacizumab.

According to the initial results from the randomized phase II CRDF-004 trial, reported in December 2024, the objective response rate (ORR) was 64% in the 30mg Onvansertib dose arm versus 33% ORR in the control arm. In the 20mg Onvansertib dose arm, the ORR was 50%. The drug candidate was well tolerated at both doses.

As of this writing, CRDF is at $3.91, down 1.51%.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [CRDF.US - Cardiff Oncology](https://longbridge.com/en/quote/CRDF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cardiff Oncology Inc. 為首席會計官 Brigitte Lindsay 提交了初始實益擁有聲明 | Cardiff Oncology Inc. 已向美國證券交易委員會提交了初步的受益所有權聲明，列出了 Brigitte Ute Lindsay 為受益所有人及首席會計官。完整的文件可以通過證券交易委員會的 EDGAR 系統訪問。此新聞簡報由 | [Link](https://longbridge.com/en/news/275360708.md) |
| 貝森特和沃什的 “導師”，德魯肯米勒 Q4“精準” 開倉金融股 ETF、標普等權重 ETF 和巴西 ETF | 科技股方面，德魯肯米勒 Q4 清倉了 Meta，加倉了谷歌與 Sea。德魯肯米勒與貝森特、沃什的 “師徒” 關係讓市場推測，“德魯肯米勒經濟學”——即反赤字、反通脹、反關税——可能通過貝森特和沃什滲透至政策制定中。 | [Link](https://longbridge.com/en/news/276214511.md) |
| Ingalls & Snyder LLC 出售了 6,891 股 Oracle 公司股票$ORCL | Ingalls & Snyder LLC 在第三季度減少了對甲骨文公司（NYSE:ORCL）12.9% 的持股，出售了 6,891 股，剩餘持有 46,676 股，價值 1,310 萬美元。其他機構投資者，包括挪威銀行和 Jennison  | [Link](https://longbridge.com/en/news/276218440.md) |
| Figma｜8-K：2025 財年 Q4 營收 3.04 億美元 |  | [Link](https://longbridge.com/en/news/276270628.md) |
| 缺電、缺水、缺人還搶地！美國數據中心建設狂潮面臨阻力 | 科技巨頭掀起的數據中心基建狂潮正遭遇嚴峻 “現實牆”：從電網容量、水資源瓶頸到技術工人短缺，執行風險急劇上升。亞馬遜等巨頭以驚人高價搶地，直接擠壓住宅開發，甚至斥資 7 億美元購入原定建房的地塊。這場資源競賽不僅推高了運營成本，更可能拖累  | [Link](https://longbridge.com/en/news/276290793.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.